Asmus Friedrich, Salih Farid, Hjermind Lena Elisabeth, Ostergaard Karen, Munz Marita, Kühn Andrea A, Dupont Erik, Kupsch Andreas, Gasser Thomas
Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, Tübingen, Germany.
Ann Neurol. 2005 Nov;58(5):792-7. doi: 10.1002/ana.20661.
Direct genomic DNA sequencing fails to detect epsilon-sarcoglycan (SGCE) mutations in up to 30% of familial myoclonus-dystonia (M-D) cases. We identified novel large heterozygous deletions of SGCE exon 5 or exon 6 in two M-D pedigrees. Like nonsense mutations, exon rearrangements result in the generation of premature stop codons downstream of the deleted exon. SGCE exon dosage assays may identify additional families with SGCE mutation and thus reduce "genetic heterogeneity."
直接对基因组DNA进行测序,在高达30%的家族性肌阵挛性肌张力障碍(M-D)病例中未能检测到ε-肌聚糖(SGCE)突变。我们在两个M-D家系中鉴定出了SGCE外显子5或外显子6的新型大片段杂合缺失。与无义突变一样,外显子重排会导致在缺失外显子下游产生过早的终止密码子。SGCE外显子剂量分析可能会识别出更多存在SGCE突变的家系,从而减少“遗传异质性”。